Sugi Predict

Sugi Predict / Compounds / SCHEMBL4587677

SCHEMBL4587677

SCHEMBL4587677

NC(=O)N(c1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.45
▸ LMNA P02545 5/20 0.43
▸ CES2 O00748 1/20 0.42
▸ CES1 P23141 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ MT-CO2 P00403 1/20 0.41
▸ ALOX15 P16050 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ MAPT P10636 3/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28834471 0.92 MEN1 (0.44) NPC1LMNACES2CES1ALDH1A1
SCHEMBL1304707 0.88 TSHR (0.63) LMNACES2CES1ALDH1A1TDP1
SCHEMBL29504742 0.87 NPC1 (0.42) NPC1LMNAALDH1A1MT-CO2TSHR
SCHEMBL337227 0.87 NPC1 (0.42) NPC1LMNAALDH1A1MT-CO2TSHR
SCHEMBL4588620 0.85 HTR3E (0.47) NPC1LMNAALDH1A1TSHRMAPT
SCHEMBL9322011 0.81 GAA (0.39) NPC1LMNACES2CES1ALDH1A1
SCHEMBL2235949 0.81 CA2 (0.66) CA1CA2
SCHEMBL11845486 0.79 NPC1 (0.50) NPC1LMNACES2CES1ALDH1A1
SCHEMBL30019653 0.79 HTR3E (0.44) LMNACYP2C19MAPTCA1CA2
SCHEMBL1525499 0.79 HTR3E (0.44) LMNACYP2C19MAPTCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110436814-A A kind of concrete high-efficiency additive and preparation method thereof LIU YANRUI 2019-11-12 — — CN claimed
CN-118344504-A Polysaccharide for preventing or treating diabetes and preparation method thereof 重庆三峡学院 2024-07-16 — — CN disclosed
CN-110436814-A A kind of concrete high-efficiency additive and preparation method thereof LIU YANRUI 2019-11-12 — — CN disclosed
US-20080269247-A1 Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-10-30 — — US disclosed
US-20080119471-A1 Piperazine urea derivatives for the treatment of endometriosis BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-05-22 — — US disclosed
US-7268140-B2 Piperazine derivatives and their use as anti-inflammatory agents SCHERING AG (DE) 2007-09-11 — — US disclosed
EP-1713483-A1 CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA Schering Aktiengesellschaft (DE) 2006-10-25 — — EP disclosed
US-20060135487-A1 Piperazine derivatives and their use as anti-inflammatory agents BAUMAN JOHN G 2006-06-22 — — US disclosed
US-6977258-B2 Piperazine derivatives and their use as anti-inflammatory agents SCHERING AKTIENGESELLSCHAFT (DE) 2005-12-20 — — US disclosed
US-6972290-B2 Piperazine derivatives and their use as anti-inflammatory agents SCHERING AKTIENGESELLSCHAFT (DE) 2005-12-06 — — US disclosed
EP-0988292-B1 PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS SCHERING AG (DE) 2003-02-12 — — EP disclosed
US-20020177598-A1 Piperazine derivatives and their use as anti-inflammatory agents SCHERING AKTIENGSCHELLSCHAFT 2002-11-28 — — US disclosed
EP-1254899-A2 Piperazine derivatives and their use as anti-inflammatory agents Schering Aktiengesellschaft (DE) 2002-11-06 — — EP disclosed
US-6281240-B1 CYSTIC FIBROSIS ELI LILLY AND COMPANY 2001-08-28 — — US disclosed
US-6207665-B1 TO TREAT INFLAMMATORY DISORDERS IN HUMANS SCHERING AKTIENGESELLSCHAFT (DE) 2001-03-27 — — US disclosed
WO-1998044799-A1 DIARYLSULFONYLUREAS FOR USE IN TREATING SECRETORY DIARRHEA ELI LILLY AND COMPANY (US) 1998-10-15 — — WO disclosed
EP-0606723-A1 Imidazolidin-2-one derivatives and their use as antitumor agents ELI LILLY AND COMPANY (US) 1994-07-20 — — EP disclosed
US-5270329-A 1-arylsulfonyl-imidazolidin-2-one derivatives ELI LILLY AND COMPANY (US) 1993-12-14 — — US disclosed
US-5262440-A Treatment of neoplasms ELI LILLY AND COMPANY (US) 1993-11-16 — — US disclosed
EP-0546763-A1 Antitumor compositions and methods of treatment ELI LILLY AND COMPANY (US) 1993-06-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135487-A1 Piperazine derivatives and their use as anti-inflammatory agents IL5, PTGES2, PTGES NPC1 970/4885LMNA 4370/4885CES2 1102/4885
US-20080269247-A1 Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis CCL2, CCR2, CXCL10 NPC1 2797/4885LMNA 2687/4885CES2 3205/4885
US-20020177598-A1 Piperazine derivatives and their use as anti-inflammatory agents IL5, PTGES2, PTGES NPC1 970/4885LMNA 4370/4885CES2 1102/4885
US-20080119471-A1 Piperazine urea derivatives for the treatment of endometriosis ESR2, GPER1, SLC14A1 NPC1 3725/4885LMNA 3761/4885CES2 2411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.